Humasis Co

Humasis Co Financial Debt Ratio

The Financial Debt Ratio of Humasis Co (205470.KQ) as of Nov 10, 2026 is 0.10 %. In the previous year, Financial Debt Ratio was 0.64 % — a change of -83.75% (lower).

Financial Debt Ratio

0.10 %

YoY

-83.75%

Last updated:

Financial Debt Ratio of Humasis Co is 2025 0.10 % . Financial Debt Ratio of Humasis Co was 2024 0.64 % . It decreases by -83.75% lower compared to the previous year.

The Humasis Co Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
30.13 KRW
Jan 1, 2019
20.00 KRW
Jan 1, 2020
17.41 KRW
Jan 1, 2021
0.66 KRW
Jan 1, 2022
0.46 KRW
Jan 1, 2023
0.03 KRW
Jan 1, 2024
0.64 KRW
Jan 1, 2025
0.10 KRW
The Humasis Co Financial Debt Ratio history
YEARFinancial Debt RatioYoY
0.10 %-83.75%
0.64 %+1,793.32%
0.03 %-92.67%
0.46 %-30.62%
0.66 %-96.20%
17.41 %-12.97%
20.00 %-33.61%
30.13 %-7.22%
32.47 %+219.58%
10.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Financial Debt Ratio of Humasis Co is 0.10 % in 2025.

Financial Debt Ratio of Humasis Co changed from 0.64 % to 0.10 %, representing a -83.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Humasis Co since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Humasis Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Humasis Co

All Key Metrics — Humasis Co